GENERAL
Generic Semaglutide Arrives, Igniting Race For India’s Diabetes Market
The expiry of the Semaglutide patent in India has triggered a high-stakes entry of domestic pharma majors into the GLP-1 therapy space, setting the stage for intense price competition and wider patient access. With type 2 diabetes and obesity emerging as major public health challenges, companies are racing to capture a share of what is […]
Sajan C Kumar
·
Mar 21, 2026
GENERAL
Dr Reddy’s Launches Semaglutide Generic Injection For Diabetes Care
Dr Reddy’s Laboratories has announced the launch of Obeda, its injectable Semaglutide, marking a significant milestone in expanding access to advanced GLP-1 receptor agonist therapies for the treatment of type 2 diabetes in India. The company claimed that it is the first Indian player to secure approval from the Drugs Controller General of India (DCGI) […]
CW Bureau
·
Mar 21, 2026
GENERAL
Zydus, Torrent Partner To Co-Market Semaglutide Injection In India
Zydus Lifesciences and Torrent Pharmaceuticals have entered into a strategic licensing and supply agreement to co-market Semaglutide injection in India, marking a significant move in the fast-growing metabolic disorders segment. Under the agreement, Zydus will manufacture and supply the drug, while Torrent Pharma will hold semi-exclusive rights to co-market it under its own brand, Sembolic, […]
CW Bureau
·
Mar 18, 2026
